Apyx Medical (APYX) AI Stock Analysis

• Market Cap: $121.40M
• Dividend Yield: N/A
• Average Volume (3M): 118.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.30
• Revenue Growth: -5.14%
• EPS Growth: 44.86%
• Country: US
• Employees: 220
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.09
• Shares Outstanding: 37,819,477
• 10 Day Avg. Volume: 115,642
• 30 Day Avg. Volume: 118,586
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: 2.18
• Enterprise Value/Gross Profit: 3.54
• Enterprise Value/Ebitda: -8.85
• 1Y Price Target: $4.00
• Price Target Upside: 27.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 50 Neutral
• Price Target: $3.00 ▼(-4.15% Downside)

Apyx Medical's overall stock score reflects significant financial challenges, with persistent losses and liquidity issues being the most critical concerns. However, technical indicators show positive momentum, and strategic initiatives discussed in the earnings call provide some optimism for future growth. The valuation remains a concern due to negative earnings and lack of dividends.

Positive Factors

Strategic Partnerships

The partnership with GlamMoon Medical Technology for Renuvion's launch in China expands Apyx's market reach, tapping into a growing aesthetic market and potentially driving long-term revenue growth.

Product Innovation

The FDA submission for AYON's label expansion to include power liposuction could position it as a comprehensive solution in body contouring, enhancing its competitive edge and market adoption.

Operational Efficiency

Improvements in operational efficiency through cost reduction and restructuring enhance Apyx's ability to manage expenses and improve profitability over time.

Negative Factors

Revenue Decline

The decline in revenue, particularly in OEM sales, indicates challenges in maintaining sales momentum, which could impact long-term financial stability and growth prospects.

Cash Flow Challenges

Persistent negative cash flows and declining growth rates highlight liquidity issues, potentially limiting Apyx's ability to invest in growth opportunities and sustain operations.

Profitability Concerns

Negative profitability metrics reflect challenges in achieving sustainable earnings, which could hinder Apyx's ability to generate shareholder value and fund future initiatives.

Apyx Medical Business Overview & Revenue Model

Company Description

Apyx Medical Corporation is a medical technology company focused on developing and commercializing innovative products for the surgical and aesthetic markets. The company specializes in advanced energy-based devices, particularly those utilizing its proprietary Renuvion technology, which combines helium plasma and radiofrequency energy for precision in soft tissue and skin procedures. Apyx Medical serves a diverse range of healthcare providers, including plastic surgeons, dermatologists, and other medical professionals, aiming to enhance patient outcomes and improve the overall efficiency of surgical procedures.

How the Company Makes Money

Apyx Medical generates revenue primarily through the sale of its Renuvion devices and consumables, which are used in various surgical and aesthetic applications. The company has established a recurring revenue model through the sale of disposable components that accompany its devices, contributing significantly to its earnings. Additionally, Apyx Medical engages in strategic partnerships with healthcare providers and distributors to expand its market reach and drive adoption of its technologies. These partnerships often include training and support services that promote the effective use of its products, further enhancing revenue opportunities. The company's focus on innovation and expanding its product portfolio also plays a critical role in attracting new customers and retaining existing ones, thereby strengthening its financial performance.

Apyx Medical Financial Statement Overview

Summary

Apyx Medical faces substantial financial challenges across all verticals. The income statement shows declining revenue and persistent losses. The balance sheet reflects improved leverage but continued negative returns. Cash flow metrics indicate liquidity issues, with negative cash flows and growth rates. Overall, the company needs to address its profitability and cash flow concerns to improve its financial health.

Income Statement

Apyx Medical's income statement reveals significant challenges. The company has experienced declining revenue growth, with a negative growth rate in the TTM period. Profitability metrics such as net profit margin and EBIT margin are negative, indicating ongoing losses. Although the gross profit margin remains relatively stable, the overall financial health is concerning due to persistent negative earnings.

Balance Sheet

The balance sheet shows a mixed picture. The debt-to-equity ratio has improved in the TTM period compared to the previous year, suggesting better leverage management. However, the return on equity remains negative, reflecting continued losses. The equity ratio indicates a moderate level of equity financing, but the company's financial stability is undermined by ongoing losses.

Cash Flow

Cash flow analysis highlights significant issues. The company has negative operating and free cash flows, with a declining free cash flow growth rate. The operating cash flow to net income ratio is negative, indicating cash flow challenges. Despite a positive free cash flow to net income ratio, the overall cash flow position is weak, raising concerns about liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	46.51M	48.10M	52.35M	44.51M	48.52M	27.71M
Gross Profit	28.67M	29.36M	33.76M	29.13M	33.60M	17.50M
EBITDA	-11.49M	-16.80M	-18.11M	-22.01M	-13.91M	-18.48M
Net Income	-17.26M	-23.46M	-18.71M	-23.28M	-15.20M	-11.91M
Balance Sheet
Total Assets	58.19M	64.84M	79.24M	51.77M	68.72M	74.11M
Cash, Cash Equivalents and Short-Term Investments	29.30M	31.74M	43.65M	10.19M	30.87M	41.91M
Total Debt	4.71M	38.76M	38.50M	796.00K	305.00K	676.00K
Total Liabilities	50.73M	50.51M	52.32M	13.98M	14.71M	10.25M
Stockholders Equity	7.25M	14.21M	26.70M	37.58M	53.70M	63.72M
Cash Flow
Free Cash Flow	-10.03M	-18.77M	-5.78M	-21.29M	-11.17M	-16.65M
Operating Cash Flow	-9.31M	-18.05M	-5.25M	-20.28M	-10.45M	-16.07M
Investing Cash Flow	-718.00K	-722.00K	6.73M	-1.01M	-723.00K	-581.00K
Financing Cash Flow	6.80M	6.75M	32.17M	217.00K	24.00K	-73.00K

Apyx Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.13
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APYX, the sentiment is Positive. The current price of 3.13 is above the 20-day moving average (MA) of 2.82, above the 50-day MA of 2.36, and above the 200-day MA of 1.75, indicating a bullish trend. The MACD of 0.23 indicates Positive momentum. The RSI at 63.59 is Neutral, neither overbought nor oversold. The STOCH value of 39.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for APYX.

Apyx Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FONR	64 Neutral	$97.55M	12.60	4.92%	―	1.43%	-20.12%
XTNT	57 Neutral	$112.14M	-22.44	-9.80%	―	15.16%	-39.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APYX	50 Neutral	$121.40M	―	-156.90%	―	-5.14%	44.86%
ANIK	46 Neutral	$144.33M	―	-22.91%	―	-25.85%	18.18%
NSPR	45 Neutral	$94.29M	-2.72	-123.51%	―	7.60%	-0.78%
RCEL	42 Neutral	$105.68M	―	-935.73%	―	38.32%	-1.31%

Apyx Medical Corporate Events

Apyx Medical’s Renuvion APR System: Promising Results in Facelift Surgery Study

Study Overview: The clinical study titled ‘Histological Evaluation of Human Skin Biopsies to Assess the Effects of Renuvion APR Treatment as an Adjunct Procedure in Facelift Surgery’ aims to evaluate the impact of the Renuvion device on skin quality. Conducted by Apyx Medical, the study focuses on measuring skin elasticity, hydration, and biological age through DNA methylation in participants undergoing lower facelift surgery.

Apyx Medical Holds Annual Stockholders Meeting

On August 7, 2025, Apyx Medical Corporation held its annual stockholders meeting where several key proposals were voted on. The stockholders elected five directors, ratified RSM US LLP as the independent accounting firm for 2025, approved executive compensation resolutions, and amended the company’s Certificate of Incorporation. These decisions are expected to influence the company’s governance and operational strategies moving forward.

The most recent analyst rating on (APYX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Apyx Medical stock, see the APYX Stock Forecast page.

Apyx Medical’s Earnings Call: Cautious Optimism Amid Challenges

Apyx Medical’s recent earnings call painted a picture of cautious optimism, highlighting several positive developments amid some challenges. The company celebrated the successful launch of the AYON system and the expansion of Renuvion into China, both of which are expected to drive future growth. However, these advancements were tempered by a decline in overall revenue and a significant drop in the OEM segment. The sentiment expressed during the call was one of careful optimism, with a focus on the potential for growth through new product launches.

Apyx Medical Reports Q2 2025 Results and Raises Guidance

Apyx Medical Corporation is an advanced energy technology company specializing in helium plasma and radiofrequency platform technology, with products such as Renuvion and the AYON Body Contouring System in the cosmetic surgery market. The company also operates in the hospital surgical market with J-Plasma.